

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1 1. (currently amended) A method for inhibiting ~~and preventing~~ a malignant cell phenotype, said method comprising: administering to cells a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that produces vasodilation.
- 1 2. (original) The method of claim 1 wherein the cells are in a subject at risk for or suffering from a malignant cell phenotype.
- 1 3. (original) The method of claim 1 or 2 wherein administration of the nitric oxide mimetic inhibits metastases and development of resistance to antimalignant therapeutic modalities in the cells.
- 1 4. (original) The method of claim 1 or 2 wherein administration of the nitric oxide mimetic inhibits development of a more aggressive malignant cell phenotype in the cells upon administration of an anti-VEGF agent.
- 1 5. (original) The method of claim 1 or 2 wherein administration of the nitric oxide mimetic inhibits development of a malignant cell phenotype in cells exposed to factors which lower cellular nitric oxide mimetic activity.
- 1 6-7. (canceled)
- 1 8. (currently amended) A method for increasing efficacy of an antimalignant therapeutic modality against cancer cells, said method comprising: administering to ~~the~~ said cells a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that produces vasodilation.

1 **9-12.** (canceled)

1 **13.** (currently amended) A method for inhibiting ~~and preventing~~ a malignant
2 cell phenotype in an animal, said method comprising: administering to ~~an~~ said animal in need
3 thereof a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than
4 a dose of said nitric oxide mimetic that produces vasodilation.

1 **14-15.** (canceled)

1 **16.** (original) The method of claim 13 wherein administration of the nitric
2 oxide mimetic inhibits tumor metastases and development of resistance to antimalignant
3 therapeutic modalities in cells in the animal.

1 **17.** (original) The method of claim 13 wherein administration of the nitric
2 oxide mimetic inhibits development of a more aggressive malignant cell phenotype in cells in the
3 animal upon administration of an anti-VEGF agent to the animal.

1 **18.** (original) The method of claim 13 wherein administration of the nitric
2 oxide mimetic inhibits development of a malignant cell phenotype in animals exposed to factors
3 which lower cellular nitric oxide mimetic activity.

1 **19.** (currently amended) A method of treating cancer in a subject, said method
2 comprising administering to ~~a~~ said subject in need thereof a low dose of a nitric oxide mimetic,
3 wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that
4 produces vasodilation.

1 **20-21.** (canceled)

1 **22.** (original) The method of claim 19 wherein the cancer is prostate cancer.

1 **23-29.** (canceled)

1 **30-32. (canceled)**

1 **33.** (new) A method for inhibiting a malignant cell phenotype, said method
2 comprising administering to cells a low dose of a nitric oxide mimetic, wherein said low dose is
3 between about 10^{-14} M to about 10^{-6} M of said nitric oxide mimetic.

1 **34.** (new) The method of claim 33, wherein said low dose is between about
2 10^{-14} M to about 10^{-10} M of said nitric oxide mimetic.

1 **35.** (new) A method for increasing efficacy of an antimalignant therapeutic
2 modality against cancer cells, said method comprising administering to said cells a low dose of a
3 nitric oxide mimetic, wherein said low dose is between about 10^{-14} M to about 10^{-6} M of said
4 nitric oxide mimetic.

1 **36.** (new) The method of claim 35, wherein said low dose is between about
2 10^{-14} M to about 10^{-10} M of said nitric oxide mimetic.

1 **37.** (new) A method for inhibiting a malignant cell phenotype in an animal,
2 said method comprising administering to said animal in need thereof a low dose of a nitric oxide
3 mimetic, wherein said low dose is between about 10^{-14} M to about 10^{-6} M of said nitric oxide
4 mimetic.

1 **38.** (new) The method of claim 37, wherein said low dose is between about
2 10^{-14} M to about 10^{-10} M of said nitric oxide mimetic.

1 **39.** (new) A method for treating cancer in a subject, said method comprising
2 administering to said subject in need thereof a low dose of a nitric oxide mimetic, wherein said
3 low dose is between about 10^{-14} M to about 10^{-6} M of said nitric oxide mimetic.

1 **40.** (new) The method of claim 39, wherein said low dose is between about
2 10^{-14} M to about 10^{-10} M of said nitric oxide mimetic.